Curis is a drug development company seeking to develop and commercialize next-generation targeted small molecule drug candidates for the treatment of cancer. Erivedge, the first and only medicine approved by the FDA to treat advanced basal cell carcinoma, is being commercialized and developed by Roche and Genentech under a collaboration between Curis and Genentech. Curis is additionally leveraging its experience in targeting signaling pathways to develop proprietary targeted cancer programs. For more information, visit the company’s Web site: http://www.curis.com
Let us hear your thoughts below: